<strong>Laura Kulik, MD</strong> will present the Hyman J. Zimmerman Hepatotoxicity State of the Art Lecture, &quot;Systemic Therapy for Hepatocellular Carcinoma in 2025: Where Are We Now?&quot;

Experts provide a case-based, in-depth tutorial on machine perfusion, donor management, and outcomes of liver transplantation using organs procured from donation after circulatory death (DCD). Topics include an overview of the various techniques of machine perfusion for DCD liver allografts, including programmatic costs; and short-term and long-term impacts of machine perfused DCD liver allografts on patient-survival, graft survival, and biliary complications. 

<strong>Harmeet Malhi, MBBS FAASLD</strong>, will present the Hans Popper State of the Art Lecture, &quot;Hacking the Hepatic Lipid Code: Mechanisms and Therapeutic Opportunities in Steatotic Liver Disease.&quot; This presentation delves into the molecular intricacies of hepatic lipid metabolism and lipotoxicity in metabolic dysfunction associated steatotic liver disease and alcohol associated hepatitis. We will review the critical mechanistic role lipids play in liver injury and inflammation in the development of steatotic liver disease. By decoding the hepatic lipid code, the presentation aims to unveil potential therapeutic strategies. Attendees will gain insights into cutting-edge mechanisms and approaches to address liver steatosis effectively.<br />
&nbsp;

Experts explore the dynamic interactions between the innate and adaptive immune systems in the context of liver fibrosis and inflammation, and provide insights into cutting-edge research and strategies for addressing liver fibrosis and associated inflammatory conditions. Key areas of focus include: (1) immune system roles—how innate immune cells (eg, macrophages, dendritic cells) and adaptive immune components (eg, T cells and B cells) communicate and influence hepatic tissue responses; (2) mechanisms of crosstalk—signaling pathways, cytokines, and cellular interactions that drive fibrosis and chronic liver inflammation; and (3) clinical implications—how immune crosstalk contributes to disease progression and identification of potential therapeutic targets to modulate the immune response and treat liver disorders.
<ul><br />
&nbsp;
</ul>

This clinical symposium focuses on unique medical and surgical aspects of selection and management of liver transplant candidates with advanced age, obesity, and/or frailty. Topics include: medical and endoscopic management of obesity before transplantation; the role of prehab for frail transplant candidates; selection of transplant candidates with advanced age; and surgical anatomical challenges in liver transplantation. 

Subject matter experts review current challenges and controversies in the management of important complications of portal hypertension, including new approaches to refractory ascites, lower gastrointestinal bleeding due to portal hypertension, and the identification of recompensation. The program also includes a case-based expert panel discussion about the management of portal hypertension in the context of other complications such as liver cancer. 

Modern hepatology regularly uses diagnostic and prognostic tools in clinical practice. Artificial intelligence (AI), telehealth, clinical decision support (CDS), and remote monitoring using wearable technology are growing fields of research that can be leveraged to advance patient care and allow care teams to work more efficiently with better, more nuanced data. This session provides an overview of recent and upcoming technological innovations in the management of patients with chronic liver disease. Targeting both clinicians and researchers, this session focuses on 4 primary topics: AI-powered electronic health records, CDS tools, telehealth, and wearable technology/remote monitoring. Presentations touch on: current shortcomings in patient care and how technological applications may improve it; ongoing research; resources currently available to clinicians; future technology; and barriers to use in clinical practice. Where applicable, presenters include an overview of the US Food and Drug Administration approval process (eg, for wearables/remote monitoring tools) and privacy concerns (eg, for AI applications). This session aims to interweave the incredible promise of the future of health care with the difficulties of the present.

Join us at this reception hosted by AASLD's Inclusion and Diversity Committee to celebrate the rich experiences and perspectives within the hepatology community. Connect with colleagues, share your journey, and engage in thoughtful conversation in a space that values connection, respect, and belonging.

Parenteral nutrition (PN) provides lifesaving nutrition to infants and children unable to feed enterally. Its use, however, may be complicated by parenteral nutrition-associated liver disease (PNALD). Experts present the pathogenesis of PNALD; PN improvements over the past few decades for hepatic protection;&nbsp;and current research updates in PNALD.<br />
<br />
&nbsp;